Archive News

2020

• - 22 Dec 2020 – Update on the recently acquired NTCD-M3 programme
• - 21 Dec 2020 – Destiny Pharma joins the Pharmabiotic Research Institute (PRI)
• - Biotech Showcase conference, 11 – 15 January 2021
• - 26 Nov 2020 – Destiny Pharma – Result of General Meeting and Total Voting Rights
• - 25 Nov 2020 – Destiny Pharma announces total gross proceeds raised via Open Offer
• - 18 Nov 2020 – Antibiotic Resistance: A Matter of Time – FT
• - Destiny Pharma to attend Jefferies Virtual London Healthcare conference, 17 – 19 November 2020
• - Destiny Pharma is supporting World Antimicrobial Resistance (#AMR) Awareness Week, 18 – 24 November 2020
• - Note to shareholders
• - Circular to shareholders dated 10 November 2020
• - Form of Proxy
• - Open Offer Application Form
• - 09 Nov 2020 – Destiny Pharma to acquire Phase 3 ready C.difficile program and announces fund raising
• - 09 Nov 2020 – Destiny Pharma to acquire Phase 3 ready C.difficile program and announces fund raising
• - Destiny Pharma to attend EWMA Virtual 2020 conference, 18 – 19 November 2020
• - 12 Oct 2020 – Clinical Study Patient Recruitment Update
• - 01 Oct 2020 – Destiny Pharma welcomes proposed PASTEUR Act in USA
• - 17 Sep 2020 – Update on Phase 2b clinical study of lead asset XF-73 in the prevention of post-surgical infections
• - 17 Sep 2020 – Interim results for the 6 months ended 30 June 2020
• - 10 Sep 2020 – Scrip article “Destiny Pharma and SporeGen back Nasal Spray over Vaccine to tackle COVID-19”
• - Destiny Pharma to attend BIO-Europe Digital, 26 – 29 October 2020
• - 07 Sep 2020 – Destiny Pharma and SporeGen® announce collaboration and Innovate UK grant award to co-develop novel, preventative treatment for COVID-19
• - 17 Aug 2020 – Destiny Pharma welcomes NBIC #BiofilmAware campaign, launched today
• - 11 Aug 2020 – Positive interim safety review of Phase 2b clinical trial of lead asset XF-73 in the prevention of post-surgical bacterial infections
• - 07 Aug 2020 – Could drug-resistant bacteria cause the next pandemic? – Forbes
• - 05 Aug 2020 – Neil Clark, CEO, interviewed by Equity Development
• - 27 July 2020 – Update on Phase 2b clinical study of XF-73
• - 10 July 2020 – Pharma companies join forces to launch $1 billion fund to develop new antibiotics by 2030
• - 10 June 2020 – Result of Annual General Meeting
• - 09 June 2020 – Grant awarded for Cardiff University collaboration
• - 12 May 2020 – Posting of Annual Report and Notice of AGM
• - 07 May 2020 – Director of Preclinical Development as panel member for KTN Antimicrobial Resistance Global Expert Mission dissemination seminar
• - 06 May 2020 – FT article highlights Coronavirus lessons for the fight against superbugs
• - 04 May 2020 – Independent review supports the potential of XF-73
• - 29 Apr 2020 – Audited results for the year ended 31 December 2019 and clinical development update
• - 08 Apr 2020 – Destiny Pharma featured in Endpoints News
• - 02 Apr 2020 – Antibiotic resistance could lead to more covid-19 deaths
• - 03 Mar 2020 – Clinical and Business Update
• - 21 Feb 2020 – Effectiveness of cancer treatments threatened by rising antibiotic resistance
• - Destiny Pharma to attend ECCMID 2020, 18 – 21 April 2020, Paris, France
• - Destiny Pharma to attend BIO-Europe Spring, 23 – 25 March 2020, Paris, France
• - Destiny Pharma to attend 4th AMR Conference: Novel Antimicrobials and AMR Diagnostics, 12 – 13 March 2020, Basel, Switzerland
• - Destiny Pharma to attend Infection Control 2020, 13 February 2020, Birmingham, UK
• - Destiny Pharma to attend the 2020 Bioinfect conference, 12th February 2020, Alderley Park, UK
• - Destiny Pharma to attend 4th AMR Conference: Novel Antimicrobials and AMR Diagnostics, 12 – 13 March 2020, Basel, Switzerland
• - Destiny Pharma to attend Infection Control 2020, 13 February 2020, Birmingham, UK
• - 22 Jan 2020 – Proactive interview – Destiny Pharma awaits key inflection point mid-2020 in its antimicrobial Phase 2b clinical trial
• - 20 Jan 2020 – Positive update on the development of new XF-platform drug formulations
• - Destiny Pharma to present at LSX World Congress 2020, 4th February 2020, London, UK
• - Destiny Pharma to present at JPM / Biotech Showcase 2020, 13 – 15 January 2020, San Francisco, USA
• - Destiny Pharma to present at LSX World Congress 2020, 4th February 2020, London, UK
• - Destiny Pharma to present at BFC Global Healthcare Investment Conference, 12 January 2020, San Francisco, USA

2019

• - 17 Dec 2019 – APSIC guidelines recommend decolonising S. aureus
• - 02 Dec 2019 – Destiny Pharma to present at the Partnerships to Tackle the Global Challenge of AMR, UK-China AMR Workshop
• - 02 Dec 2019 – Directorate Change
• - Destiny Pharma to present at JPM / Biotech Showcase 2020, 13 – 15 January 2020, San Francisco, USA
• - Destiny Pharma to attend RSC Novel Strategies for Combatting Antibacterial Resistance event, 9 December 2019, London, UK
• - Destiny Pharma to attend UK-China AMR Workshop 2019, 3 – 5 December 2019, Beijing, China
• - 15 Nov 2019 – Destiny Pharma to present at the Inv€$tival Showcase in partnership with Jefferies
• - Destiny Pharma to present at Emerging Antimicrobials and Diagnostics in AMR 2019 on 19-20 November 2019 in Amsterdam
• - Destiny Pharma to attend Jefferies 2019 London Healthcare Conference on 20-21 November 2019 in London, UK
• - 06 Nov 2019 – Destiny Pharma to present at the World Anti‐Microbial Resistance Congress 2019
• - 16 Oct 2019 – Positive Phase 1 results published in journal
• - Destiny Pharma to present at World Anti-Microbial Resistance Congress 2019, 7 – 8 November 2019, Washington DC, USA
• - Destiny Pharma to present at Life Science IP, 26 – 27 November 2019, London, UK
• - 24 Sep 2019 – Destiny Pharma Interim results presentation and audio recording
• - 23 Sep 2019 – Directorate change
• - 23 Sep 2019 – Interim results for the 6 months ended 30 June 2019
• - 11 Sep 2019 – Public Health England announced its new strategy to address AMR
• - Destiny Pharma to attend BIO-Europe 2019, 11 – 13 November 2019, in Hamburg, Germany
• - Destiny Pharma to attend CPhI Europe, 5 – 7 November 2019, in Frankfurt, Germany
• - Destiny Pharma to attend IDWeek 2019, 2 – 6 October 2019, in Washington DC, USA
• - 10 Sep 2019 – Destiny Pharma awarded grant to fund a research collaboration with the University of Sheffield targeting ophthalmic bacterial and fungal infections
• - 02 Sept 2019 – Destiny Pharma XF Drug platform data to be presented at EuroBiofilms
• - 15 Aug 2019 – Change in Shareholding
• - 05 Aug 2019 – Destiny Pharma welcomes the US government’s healthcare reform for novel antibacterial drug payments
• - 31 Jul 2019 – Destiny Pharma to present at the 2019 Gordon Research Conference – 4-9 August 2019
• - 17 Jul 2019 – Destiny Pharma to attend Eurobiofilms 2019, 3 – 6 September 2019 in Glasgow, Scotland
• - 17 Jul 2019 – Destiny Pharma to attend ASM-ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, 4 – 6 September 2019 in Boston, USA
• - 10 Jul 2019 – Development of new antibiotics encouraged with new pharmaceutical payment system
• - 26 Jun 2019 – Destiny Pharma participated in the UK Global Expert Mission ‘Antimicrobial resistance Germany’
• - 04 Jun 2019 – Result of AGM
• - 05 Jun 2019 – Destiny Pharma to attend OBN BioTuesday on Tuesday 16th July 2019 in Manchester, UK
• - 20 May 2019 – Destiny Pharma are part of the UK government Global Expert Mission delegation to Germany, 20-24 May 2019
• - 09 May 2019 – Pharmafocus publish article “The global rise in antibiotic resistance threatens infection prevention and cure”
• - 09 May 2019 – Destiny Pharma appoints NOMAD and Joint Broker
• - 09 May 2019 – Destiny Pharma to present at the US-China Bio-Partnering Forum, 30-31 May 2019, Chicago, USA
• - 02 May 2019 – Destiny Pharma welcomes United Nations report
• - 29 Apr 2019 – Posting of Accounts and Notice of AGM
• - 16 Apr 2019 – Equity Development publish latest research note ‘Destiny Pharma – Bucking the Big Pharma trend’
• - 15 Apr 2019 – Destiny Pharma welcomes new BEAM Alliance paper “A new vision for AMR innovation to support medical care”
• - 11 Apr 2019 – Destiny Pharma 2018 Final Results – finnCap and Edison latest published research – April 2019
• - 09 Apr 2019 – Audited Results for the year ended 31 December 2018
• - 27 Mar 2019 – Destiny Pharma to attend BioEquity Europe 2019, 20 – 21 May 2019, Barcelona, Spain
• - 27 Mar 2019 – Destiny Pharma to attend BioTrinity 2019, 30 April – 1 May 2019, London, UK
• - 27 Mar 2019 – MedPharm to develop new XF-drug formulations
• - 22 Mar 2019 – Notice of Full Year Results
• - 19 Mar 2019 – Destiny Pharma to attend European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 13 – 16 April 2019, Amsterdam, Netherlands
• - 25 Feb 2019 – Edison Investment Research publish Research Note on Destiny Pharma entitled “Prevention is commercially cost effective”
• - 17 Feb 2019 – Destiny Pharma to attend BIO-Europe Spring, 25 – 27 March 2019, Vienna, Austria
• - 30 Jan 2019 – Neil Clark, CEO, interviewed at Proactive Investor event on 28 January 2019
• - 28 Jan 2019 – Second positive Phase 1 trial data for XF-73
• - 25 Jan 2019 – Destiny awarded new UK-China AMR grant
• - 24 Jan 2019 – Destiny Pharma notes UK 5-year action plan on AMR
• - 17 Jan 2019 – Destiny Pharma to attend Superbugs & Superdrugs 2019, 18 – 19 March 2019, London, UK
• - 17 Jan 2019 – Destiny Pharma to attend Novel Antimicrobials and AMR Diagnostics 2019, 14 – 15 March 2019, Berlin, Germany
• - 17 Jan 2019 – Destiny Pharma to attend UKRI AMR House of Commons Event, 13 February 2019, London, UK

2018

• - Destiny Pharma notes Daily Telegraph coverage on antibiotic resistance
• - Destiny Pharma announces research collaboration with the University of Southampton targeting infections in diabetic foot ulcers and cystic fibrosis
• - Directorate Change
• - Destiny Pharma to attend 2018 BioInfect Conference, November 8th 2018, Cheshire, UK
• - UK government highlights global threat of AMR
• - BIA celebrates UK bioscience innovative
• - Destiny Pharma to attend Biotech Showcase, January 7th – 9th 2019, San Francisco, USA
• - Destiny Pharma to attend BioJapan, 10-12 October 2018, Pacifico Yokohama, Japan
• - Destiny Pharma announces appointment of Chief Medical Officer
• - Interim results for the 6 months ended 30 June 2018
• - Destiny Pharma to attend CPhI, 9-11 October 2018, Feria de Madrid, Spain
• - Directorate Change
• - 26 Jul 2018 – Destiny Pharma announces positive data from XF-73 Phase 1 skin irritation study
• - 17 Jul 2018 – Research collaboration with Aston University to investigate new XF-platform drug candidates
• - Destiny Pharma to attend ID Week, 3-7 October 2018, in San Francisco, USA
• - Destiny Pharma to present at Shares Investor Event, 10th July 2018, in London, UK
• - 03 Jul 2018 – Destiny Pharma welcomes significant PULL incentive
• - 14 Jun 2018 – Destiny Pharma notes FDA statement on their focus to enable new approaches to fight AMR
• - 30 May 2018 – Scientific Advisory Board
• - Destiny Pharma to attend Bio-Europe 2018, 5th – 7th November 2018, in Copenhagen, Denmark
• - Destiny Pharma to attend ASM Microbe 2018, 7th – 11th June 2018, in Atlanta, USA
• - Destiny Pharma to speak at the second meeting of the UK BioIndustry Association’s China Special Interest Group in London on 2nd May 2018
• - 23 Apr 2018 – Posting of Accounts and Notice of AGM
• - 12 Apr 2018 – Clinical update
• - 12 Apr 2018 – Audited results for the year ended 31 December 2017
• - Destiny Pharma attending International Conference on Porphyrins and Phthalocyanines (ICPP) in Munich, Germany from 1st – 6th July 2018
• - 22 Mar 2018 – Cost of antibiotic-resistant infections in U.S. tops $2B per year
• - 23 Mar 2018 – Destiny Pharma to announce financial results for the year ended 31 December 2017 on Thursday 12 April 2018
• - 22 Mar 2018 – Appointment of Joint Broker
• - 15 Mar 2018 – Destiny Pharma announces FDA Fast Track Designation for lead clinical candidate, exeporfinium chloride (XF-73)
• - Destiny Pharma attending ECCMID 2018 in Madrid, Spain from 21st – 24th April 2018
• - Destiny Pharma attending Superbugs and Superdrugs 2018 in London from 19th – 20th March 2018
• - 02 Feb 2018 – Destiny Pharma opens IND for its novel anti-infective drug XF-73 ahead of commencing US clinical trials
• - Destiny Pharma attending the 11th Berlin Conference on Life Sciences – Novel Antimicrobials and AMR Diagnostics on 2 March 2018
• - Destiny Pharma attending BioEurope Spring 2018 in Amsterdam from 12th – 14th March 2018
• - Destiny Pharma presenting at the Guinness AIM Investor Seminar in London on 22nd February 2018
• - 05 Feb 2018 – Destiny Pharma wins Deal of the Year at the Insider South East Dealmaker Awards 2018
• - 29 Jan 2018 – $1bn rewards proposed at Davos 2018 for new antibiotics
• - Destiny Pharma attending the Biotech and Money World Congress in London on 5th–6th February 2018
• - 09 Jan 2018 – Equity Development initiates coverage of Destiny Pharma

2017

• - 01 Dec 2017 – China Medical System Holdings Limited invests £3.0 million in Destiny Pharma
• - 01 Dec 2017 – Regional development and commercialisation agreement finalised with China Medical System Holdings Limited
• - 30 Oct 2017 – MRSA superbug spreading from hospitals across UK
• - 09 Oct 2017 – United Nations group to meet in Berlin in October 2017 to discuss global issue of Anti-Microbial Resistance
• - 27 Sep 2017 – Destiny Pharma to push ahead with next-generation antibiotic after £15 million IPO
• - 27 Sep 2017 – Destiny Pharma announce interim results 27th September 2017
• - 19 Sep 2017 – More support announced for new antibiotics
• - 04 Sep 2017 – Framework Agreement with China Medical Systems
• - 04 Sep 2017 – Admission and First Day of Dealings on AIM
• - 01 Sep 2017 – Destiny Pharma plc publishes Supplementary AIM Admission Document
• - 29 Aug 2017 – Destiny Pharma plc publishes AIM Admission Document
• - 18 Aug 2017 – Notification of Intention to Admit Shares to Trading on the Alternative Investment Market of the London Stock Exchange
• - 13 Jul 2017 – G20 Declaration on Combatting Antimicrobial Resistance (AMR) 7-8th July 2017
• - 07 Jul 2017 – To the G20: Incentivise Antibacterial Drug R&D
• - 07 Jul 2017 – Destiny’s Brainchild (South East Business Magazine)
• - 14 Jun 2017 – Regulators from EU, U.S. and Japan join forces on antimicrobial trials
• - Destiny Pharma in attendance at the 18th Bio€quity Europe Meeting, Paris, France
• - 09 May 2017 – Destiny Board Member Elected to the Academy of Medical Sciences
• - 13 Apr 2017 – Destiny Pharma announces appointment of new CEO
• - Destiny Pharma to attend the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna, Austria
• - Destiny Pharma to attend Bio-Europe Meeting, Barcelona, Spain
• - Destiny Pharma to present at the 18th BioEquity Europe Meeting, Paris, France

2016

• - 16 Dec 2016 – 21st Century Cures Act signed into law by President Obama
• - 30 Nov 2016 – Destiny Pharma CEO appointed to the board of GAMRIF
• - 31 Oct 2016 – Wellcome Trust report on boosting development of new antimicrobial drugs
• - Destiny Pharma to attend IDWeek in New Orleans, Louisiana
• - 21 Sep 2016 – Momentous Step taken by UN to Fight Antibiotic Resistance welcomed by Destiny Pharma
• - 05 Sep 2016 – Press Release: Novel Antibacterial Drug, exeporfinium chloride, Delivers Encouraging Safety, Tolerability and Efficacy Data in US Clinical Trial
• - Destiny Pharma Expert View Published in The Pharma Letter
• - Destiny Pharma invited to present at the inaugural Superbugs & Superdrugs USA Conference & Exhibition on the 14th and 15th November 2016 in New Jersey, USA
• - 19 May 2016 – Destiny Pharma Welcomes O’Neill Report on Tackling Antimicrobial Resistance (AMR)
• - 18 Mar 2016 – Destiny Pharma: ‘In the News.’
• - 26 Jan 2016 – Destiny Pharma sign Declaration to fight antibiotic resistance

2015

• - 11 Nov 2015 – Press Release: Destiny Pharma Announces Qualified Infectious Disease Product Designation Granted by US FDA for Novel Antibacterial Product In Development for Prevention of Post-Surgical Staphyloccocal Infections
• - 22 Oct 2015 – G7 Health Minsters committed to tackle antimicrobial resistance
• - 06 Oct 2015 – BEAM (Biotechs from Europe innovating in Anti-Microbial resistance) Alliance release first position paper identifying the key actions required to reinvigorate investment and R&D in the antibacterial field
• - 24 Aug 2015 – Latest figures from Public Health England show that the number of Methicillin Sensitive Staphylococcus aureus (MSSA) blood infection (bacteraemia) cases continue to rise in the UK
• - 23 Jun 2015 – Destiny Pharma participates in the launch of the Antibiotic Discovery Global Network
• - Destiny Pharma to attend the Society for Healthcare Epidemiology of America (SHEA) Spring 2015 Conference: Science Guiding Prevention in Orlando, Florida
• - Destiny Pharma invited to present at the inaugural Pipeline Corner event to be held during the 25th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) meeting in Copenhagen, Denmark on the 25-28th April 2015
• - 05 Feb 2015 – Global Innovation Fund recommended to be set up to support new ideas to combat antimicrobial resistance
• - 08 Jan 2015 – Destiny Pharma to attend DRIVE-AB (Driving reinvestment in R&D and the responsible use of antibiotics) meeting in London on February 9th

2014

• - 19 Dec 2014 – Drug-resistant superbugs could cost up to $100 trillion and cause 10 million extra deaths a year by 2050
• - 05 Dec 2014 – Destiny Pharma invited to attend the first event of the Review on Antimicrobial Resistance Meeting chaired by Jim O’Neill and hosted by the Wellcome Trust on the 11th December 2014
• - 17 Nov 2014 – Antibiotic Awareness Day
• - 01 Oct 2014 – Destiny Pharma to attend IDWeek in Philadelphia, PA
• - 29 Sep 2014 – Obama Administration Takes Actions to Combat Antibiotic-Resistant Bacteria
• - 04 Sep 14 – Destiny Pharma to attend 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Conference in Washington DC
• - 04 Aug 2014 – Angel CoFund join UK investors in £2.8m investment for Superbug Killing Company
• - 01 Jul 2014 – David Cameron says that superbugs can cast “world back into the dark ages of medicine”
• - 01 Apr 2014 – Destiny Pharma to attend 24th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) Conference in Barcelona, Spain
• - 01 Jan 2014 – January 2014: ADAPT Act to Spur Antibiotic Development

2013

• - 20 Dec 2013 – Destiny Pharma to attend 32nd Annual J.P. Morgan Healthcare Conference, San Francisco
• - 18 Nov 2013 – 6th European Antibiotic Awareness Day
• - 07 Nov 2013 – Destiny Pharma to attend BioInfect 2013 Conference
• - 24 Sep 2013 – Report by CDC details today’s drug-resistant health threats
• - 19 Sep 2013 – UK Government publish strategy to combat antimicrobial resistance between 2013 and 2018
• - 20 May 2013 – Press Release: Part 2 of NIAID-funded US clinical trial of anti-staphylococcal nasal gel XF-73 begins enrollment
• - 01 Mar 2013 – Chief Medical Officer Dame Sally Davies publishes annual report providing a comprehensive overview of the threat of antimicrobial resistance and infectious diseases
• - 01 Feb 2013 – New US Therapeutic Guidelines on Antimicrobial Prophylaxis published which recommend that all higher risk surgeries should now decolonise all patients with documented colonisation with S. aureus and not just MRSA
• - 01 Jan 2013 – US ICU infection rate cut by 44% by Universal bacterial Decolonisation – Hospital Corporation of America (HCA) ICU’s to adopt this regimen during early 2013
• - 01 Jan 2013 – Chief Medical Officer Dame Sally Davies says that antibiotic-resistant diseases pose “Apocalyptic” threat and tells MPs that the issue should be added to the UK Government’s national risk register of civil emergencies

2012

• - 17 Oct 2012 – National Institutes of Health launch US clinical trial of XF-73, a new anti-Staphylococcal drug
• - 01 Jul 2012 – Generating Antibiotic Incentives Now (GAIN) Act passed by US Senate on 26th June 2012
• - 26 Mar 2012 – Press Release: IND opens for anti-Staphylococcal drug XF-73 and NIAID-funded US clinical trial begins

2011

• - 04 Nov 2011 – Press Release: Sir Nigel Rudd to lead company behind MRSA cure

 

Archive

2021

2020 & Prior